Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
MERIDIA is an oral capsule small-molecule weight-management agent approved in 1997 by Abbott. The specific mechanism of action and therapeutic indications are not documented in available data. This product represents a mature pharmaceutical asset in its lifecycle.
As LOE approaches, commercial teams face declining market share with competitive pressure at 30%; expect smaller brand team and potential restructuring.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
An Observational Study to Investigate the Effects of Rapid Transmeridian Travel
Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)
A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder
Worked on MERIDIA at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Career opportunities on MERIDIA are limited, with zero linked job postings indicating minimal hiring momentum. This LOE-stage product offers defensive rather than growth-oriented career development, suitable for professionals managing portfolio wind-down or generic transition strategies.